Modern Management of Tamak Shwas (Bronchial Asthma)

1. Concept and Correlation

• Shwasa Kricchrata (difficulty breathing, dyspnea)
• Ghurghuraka (wheezing/rhonchi)
• Kasa (cough)
• Parswa Shoola (chest tightness)
• Neck stiffness, Kapha rhinorrhoea
• Orthopnea (inability to lie down - must sit up)
• During severe attacks: prominent eyeballs, fainting, profuse sweating, hoarse voice, difficulty expectorating

2. Modern Medical Understanding

• Reversible airflow obstruction
• Airway hyperresponsiveness
• Episodic wheezing, dyspnea, chest tightness, and cough
• Triggered by allergens, infections, cold air, exercise, stress, pollution

3. Modern Pharmacological Management - GINA Stepwise Approach

Step 1 - Mild Intermittent Asthma

• SABA (short-acting beta-2 agonist) - albuterol/salbutamol via MDI as rescue inhaler
• Modern GINA now recommends low-dose ICS + formoterol as rescue even at Step 1 (recognizing the inflammatory nature of asthma)
• Trigger avoidance and environmental control

Steps 2-3 - Mild to Moderate Persistent Asthma

• Low-dose ICS (e.g., beclomethasone, budesonide, fluticasone) - first-line controller
• Step 3: Low-dose ICS + LABA (long-acting beta-2 agonist - formoterol, salmeterol) combination
• Alternative: ICS + LTRA (leukotriene receptor antagonist - montelukast)
• Theophylline: historically used but now last-line due to narrow therapeutic index

Step 4 - Moderate to Severe Persistent Asthma

• Medium-to-high dose ICS + LABA
• Add-on: tiotropium (long-acting muscarinic antagonist)
• Add-on: LTRA

Step 5 - Severe/Refractory Asthma (Biologic era)

• Anti-IgE therapy: Omalizumab - for allergic asthma with elevated IgE
• Anti-IL-5/IL-5R: Mepolizumab, benralizumab - for eosinophilic asthma
• Anti-IL-4R: Dupilumab - for type 2 inflammation (eosinophilic + atopic)
• Oral corticosteroids only as last resort (lowest effective dose)

4. Management of Acute Exacerbations (Vegakalina)

Initial Assessment

• Peak expiratory flow (PEF) or FEV1, pulse oximetry, ABG if severe
• Physical exam: use of accessory muscles, ability to complete sentences, SpO2
• Chest X-ray only if pneumothorax suspected
• Warning sign: Normalization of PaCO2 without clinical improvement = impending respiratory failure

Acute Pharmacotherapy

• SABA + ipratropium combination at initiation reduces hospitalization rates
• Systemic corticosteroids are unequivocally first-line - early administration is key
• Discharge: Prednisone 40 mg/day x 5-7 days + initiate/increase ICS
• Option: Quadrupling ICS dose as alternative to oral steroids in mild-moderate exacerbations

5. Ayurvedic Management of Tamak Shwas

Phase 1 - Nidana Parivarjana (Avoidance of Causative Factors)

• Avoid cold, damp, dusty environments (Sheeta, Ruksha nidanas)
• Avoid heavy, cold, incompatible foods (Viruddha Ahara)
• Avoid smoke, strong smells, emotional stress

Phase 2 - Vegakalina Chikitsa (During Acute Attack)

• Swedana (Sudation/fomentation) - to liquefy and mobilize Kapha
• Dhumapana (medicated smoking) - with Yashtimadhu, Haritaki to open airways
• Sitopadi Churna or Shwasa Kuthara Rasa - fast-acting formulas
• Hot water (Ushna Jala) drinking to dilute Kapha
• Posture: upright sitting (correlates with orthopnea management)

Phase 3 - Avegakalina Chikitsa (During Remission)

• Vamana (therapeutic emesis) - primary treatment; eliminates vitiated Kapha from Amashaya; classically described as most beneficial in Tamak Shwas ("Vamana Udeeriyate Bhushtaram")
• Virechana (therapeutic purgation) - clears Mala-rupa Kapha from Pranavaha Srotas
• Nasya (nasal instillation) - Anu Taila or medicated oils for upper airway
• Abhyanga (oil massage) - Bala Taila or Mahanarayan Taila for Vata pacification

• Pippali Rasayana, Chyawanprash
• Aims to rebuild lung tissue (Fupphusa Sara), strengthen Ojas, reduce episodic frequency

6. Integrative (Combined) Approach - Current Evidence Direction

• Improve lung function (FEV1, PEF)
• Reduce frequency and severity of exacerbations
• Allow dose reduction of corticosteroids
• Address triggers and immune dysregulation at root level

• Warm, light, easily digestible food
• Avoid cold drinks, curd, heavy curries, fried foods, bananas
• Prefer garlic, ginger, black pepper, warm soups
• Drink warm water throughout the day

7. Monitoring and Follow-Up

Key Points Summary

1. Tamak Shwas = Bronchial Asthma - Vatakaphaja disorder of Pranavaha Srotas
2. Acute management (both systems): bronchodilators (SABA) + anti-inflammatory (corticosteroids / Shwasa Kuthara Rasa + Swedana)
3. Chronic management: GINA stepwise (ICS backbone) with Ayurvedic herbal adjuncts
4. Biologics (omalizumab, mepolizumab, dupilumab) are the modern frontier for severe refractory asthma
5. Panchakarma (especially Vamana) is the Ayurvedic equivalent of disease-modifying therapy
6. Integration - the two systems are increasingly viewed as complementary, not competing

• Murray & Nadel's Textbook of Respiratory Medicine, p. 612-622
• Fishman's Pulmonary Diseases and Disorders, pp. 808-810
• Washington Manual of Medical Therapeutics, pp. 335-337
• JAIMS Integrative Analysis of Tamaka Svasa and Bronchial Asthma

Management of Bronchial Asthma

Overview and Goals

• Achieve and maintain symptom control (daytime symptoms ≤2 days/week, no nocturnal awakenings, normal activity, reliever use ≤2 days/week)
• Minimize risk of future exacerbations, fixed airflow limitation, and medication side effects
• Match treatment to the individual patient's phenotype, comorbidities, and preferences

PART 1 - CHRONIC (LONG-TERM) MANAGEMENT

GINA 2025 Treatment Tracks for Adults and Adolescents

TRACK 1 (Preferred) - ICS-Formoterol as Reliever Across All Steps

TRACK 2 (Alternative) - SABA or ICS-SABA as Reliever

Controller Drug Classes (Chronic Therapy)

• Beclomethasone dipropionate (BDP), budesonide, fluticasone, ciclesonide, mometasone
• Reduce airway inflammation, hyperresponsiveness, exacerbations, and asthma mortality
• Standard starting dose: low-dose ICS (e.g., BDP 200 mcg/day); titrate to minimum effective dose
• Step down after 3 months of stable control

• Formoterol, salmeterol (combined with ICS - never as monotherapy)
• Complementary molecular action with ICS; more efficacious than high-dose ICS alone
• Formoterol has rapid onset, making it usable as both MART reliever and maintenance

• Tiotropium bromide
• Addition to ICS/LABA significantly decreases exacerbations and improves lung function
• Recent evidence supports triple ICS/LABA/LAMA combination (umbrella [systematic review, 2024, PMID: 38864834] shows significant exacerbation reduction)

• Montelukast
• Alternative to ICS at Step 2; less effective than ICS/LABA
• Useful when ICS adherence is a barrier or in exercise-induced bronchospasm

• Historical utility; now last-line due to narrow therapeutic index and the wide availability of safer options - Washington Manual of Medical Therapeutics

Step 5 - Severe/Refractory Asthma - Biologic Therapy

• High blood eosinophils (BEC): predicts response to all biologics
• High FeNO: predicts best response to dupilumab, omalizumab, tezepelumab
• Anti-IL-5/IL-5R efficacy: independent of FeNO levels
• Anti-IL-5/5R reduce severe exacerbations by 47-54%; anti-IL-4R reduces exacerbations by 56%

Non-Pharmacological and Adjunct Strategies

• Trigger avoidance: allergens (house dust mite removal reduces severity), occupational agents, tobacco smoke, NSAIDs (aspirin-exacerbated asthma)
• Vaccinations: annual inactivated influenza vaccine; pneumococcal vaccine (Pneumovax) for adults 19-64 with chronic asthma
• Allergen immunotherapy (AIT): subcutaneous or sublingual (HDM-SLIT); consider for patients with clinically relevant sensitization and inadequately controlled (but stable) asthma
• Smoking cessation (mandatory - smoking worsens ICS response)
• Weight reduction in obese patients (obesity drives poorly controlled asthma)
• Pulmonary rehabilitation / breathing exercises (Buteyko, physiotherapy)
• Written Asthma Action Plan: all patients must have one - self-management guide for when to increase reliever, when to add OCS, and when to seek emergency care

Step-Down Therapy

PART 2 - ACUTE EXACERBATION MANAGEMENT

Assessment of Severity

• Previous near-fatal asthma or intubation
• Current/recent hospitalization
• Overuse of SABAs or underuse of ICS
• Recent oral corticosteroid use
• Poor adherence to action plans
• Comorbid psychiatric illness

Treatment Algorithm for Acute Exacerbation

• Mild-Moderate: Salbutamol/albuterol 2.5 mg via nebulizer OR 2-6 puffs via MDI + spacer, every 20 min x 3
• Severe: Salbutamol 2.5-5 mg + Ipratropium 0.5 mg via nebulizer q20 min (combination reduces hospitalization rate at initiation), OR continuous salbutamol 10-15 mg over 1 hour with cardiac monitoring
• Levalbuterol 1.25-2.5 mg q20 min can substitute for salbutamol but shows no fewer side effects in adults

• Prednisone/prednisolone 40-60 mg/day orally - oral is as effective as IV when absorbed
• Early administration is the single most important intervention - reduces hospitalization need and speeds recovery
• Taper only after objective improvement (PEF >70% or 36-48 hrs of stability)
• Standard course: 7-14 days tapering with ICS started concurrently
• Discharge: prednisone 40 mg/day x 5-7 days + initiate/increase ICS

• Target SpO2 94-98% (adults); avoid over-oxygenation

• IV Magnesium sulfate 2 g over 20 min - reduces hospitalization in severe exacerbations; improves FEV1
• Theophylline/aminophylline: last-resort only (high toxicity, no advantage over above therapies)
• Heliox (helium-oxygen mixture): may reduce work of breathing in severe obstruction
• Non-invasive ventilation (BiPAP/CPAP): bridge therapy before intubation in impending failure
• Intubation and mechanical ventilation: life-threatening cases; permissive hypercapnia strategy; use low tidal volumes

• Failure to respond to albuterol within 30-60 min
• PEF persistently <70% of baseline after treatment
• SpO2 <92% on room air
• Prior life-threatening attack, recent hospitalisation

• PEF >70% predicted on two measurements 1 hour apart
• Prescribe OCS course + ICS step-up
• Review trigger, adherence, inhaler technique
• Follow-up within 7 days

PART 3 - MONITORING

Summary - Key Management Principles

1. GINA 2025: ICS-formoterol as reliever is preferred over plain SABA across all steps - it addresses both bronchospasm and inflammation with every puff
2. ICS is the backbone of chronic therapy - never omit in persistent asthma
3. LABA never as monotherapy - always combine with ICS
4. LAMA (tiotropium) adds significant benefit at Steps 4-5
5. Biologics have transformed Step 5 care - always phenotype before selecting
6. Acute exacerbations: SABAs + ipratropium + systemic corticosteroids started early = standard of care; magnesium sulfate for severe/refractory cases
7. Step down when controlled - avoid overtreatment
8. Action plan + patient education are non-negotiable components of every management plan

• Fishman's Pulmonary Diseases and Disorders, pp. 808-812
• Murray & Nadel's Textbook of Respiratory Medicine, pp. 612-622, 1454
• Washington Manual of Medical Therapeutics, pp. 334-337
• GINA 2025 Summary Guide (updated June 2025)
• ICS/LABA/LAMA triple therapy [umbrella systematic review, 2024, PMID: 38864834]

Bronchial Asthma - Management Summary

Core Principle

Chronic Management - GINA 5-Step Approach

• LTRA (montelukast): alternative/add-on at Steps 2-4
• Theophylline: last-line only (narrow therapeutic index)
• LABA never given as monotherapy - always with ICS

Step 5 Biologics (Severe/Refractory Asthma)

Acute Exacerbation Management

1. Short-acting bronchodilator (SABA): salbutamol 2.5 mg nebulized or 2-6 puffs MDI q20 min x3
2. Ipratropium 0.5 mg added in severe exacerbations (reduces hospitalization)
3. Systemic corticosteroids: prednisone 40-60 mg/day orally - start immediately, do not delay
4. Oxygen: target SpO2 94-98%
5. IV Magnesium sulfate 2 g over 20 min - for severe/refractory cases
6. ICU: NIV or intubation if failing despite above

Non-Pharmacological

• Trigger avoidance (allergens, smoke, cold air, NSAIDs)
• Annual influenza vaccine + pneumococcal vaccine
• Allergen immunotherapy (for stable allergic asthma)
• Smoking cessation, weight loss (obese patients)
• Written Asthma Action Plan for every patient

Step-Down Rule

Quick Memory Aid

"Assess - Adjust - Review" (GINA personalized care cycle)

• ICS = always the backbone
• ICS-formoterol = preferred single inhaler for both relief and maintenance
• Biologics = phenotype first, then choose
• Exacerbation = SABA + steroids early, magnesium for severe

VAMAN KARMUKATVA

MODE OF ACTION

• Induction of emesis
• Mobilization of doshas
• Expulsion through mouth in the form of vomiting
• Purification of srotas (channels)
• Stabilization, drainage and clearance
• Re-establishment of normal state
• Disease alleviation (Vamana)

PROPERTIES OF DRUGS USED

• Ushna (Hot) - Increases digestive fire and liquefies doshas.
• Tikshna (Sharp) - Penetrates deep and dislodges doshas.
• Sukshma (Subtle) - Reaches micro channels and mobilizes doshas.
• Vyavayi (Spreading) - Spreads throughout the body and brings doshas to the stomach.
• Vikasi (Expansive) - Expands the channels and expels doshas efficiently.

DETAILED SEQUENCE OF VAMAN KARMUKATVA

SUMMARY

• Vaman karmukatva is the process in which emesis is induced intentionally using drugs possessing the properties of Ushna, Tikshna, Sukshma, Vyavayi and Vikasi.
• These drugs mobilize the doshas from their sites and bring them to the stomach.
• The doshas are then expelled through the mouth as vomitus.
• This process cleanses the upper channels and removes accumulated doshas and Ama (toxins).
• Proper differentiation and expulsion of doshas leads to relief from diseases.
• The main benefit is purification of the body and restoration of normal balance.

THE ACT OF VOMITING (Diagram)

• Soft palate
• Closure of glottis
• Respiration stop
• Somatomotor signals → Abdominal pressure
• Stomach squeeze
• Antiperistalsis
• Contraction of diaphragm and abdominal muscles
• LES (Lower Oesophageal Sphincter) relaxation
• Cascade of vomit

VAMAN KARMUKATVA

(Mechanism of Action of Therapeutic Emesis)

Definition

"Vamana is the best treatment for Kapha disorders" - Charaka Samhita

Properties of Vamana Dravya (Drugs Used)

Mode of Action - Step-by-Step Sequence

Step 1 - Induction of Emesis

Step 2 - Mobilization of Doshas

Step 3 - Expulsion through Mouth (Urdhvabhaga Harana)

Step 4 - Purification of Srotas (Channels)

• Pranavaha Srotas (respiratory channels)
• Annavaha Srotas (upper GI tract)
• Udakavaha Srotas (water channels)
• Rasavaha Srotas (nutrient channels)

Step 5 - Dosha Differentiation (Uttama Guna)

Step 6 - Dosha Excretion (Tikshna Guna)

Step 7 - Stabilization, Drainage, and Clearance

Step 8 - Re-establishment of Normal Dosha State

• Udgara (belching) - air expulsion indicates cleared channels
• Laghuta (lightness in the body and chest)
• Uru-kamp (vibration/trembling in the throat)
• Clarity of mind and sense organs
• Feeling of relief and satisfaction
• Subsidence of symptoms

Step 9 - Disease Alleviation (Vamana Phala)

The Act of Vomiting - Modern Physiological Explanation

• Hypothalamus
• Cerebellum
• Labyrinth (vestibular system)
• Area Postrema (chemoreceptor trigger zone - CTZ)

1. Somatomotor signals sent to respiratory and abdominal muscles
2. Respiration stops (prevents aspiration)
3. Closure of glottis (protects airway)
4. Soft palate rises (closes nasopharynx)
5. LES (Lower Oesophageal Sphincter) relaxes
6. Diaphragm and abdominal muscles contract forcefully (increases intraabdominal pressure)
7. Stomach squeeze + Antiperistalsis (reverse peristaltic waves move content upward)
8. Cascade of vomit expelled through mouth

Ayurvedic-Modern Correlation

Indications of Vamana (diseases treated)

• Tamak Shwas (Bronchial Asthma) - primary indication
• Kasa (chronic cough)
• Kushtha (skin disorders - psoriasis, eczema)
• Medoroga (obesity)
• Prameha (diabetes mellitus type 2)
• Urticaria, allergic conditions
• Aruchi (anorexia), Chardi (nausea)
• Visha (poisoning - rapid elimination)
• Best performed in Vasanta Rutu (Spring season) - natural Kapha season

Contraindications (Avamya)

Paschat Karma (Post-Vamana Care)

• Samsarjana Krama - graduated dietary protocol (most important post-procedure step)
  • Day 1-2: Peya (thin rice gruel)
  • Day 3-4: Vilepi (thick rice gruel)
  • Day 5-6: Akrita Yusha (unseasoned soup)
  • Day 7: Krita Yusha (seasoned soup)
  • Day 8+: Normal diet gradually reintroduced
• Dhoomapana (medicated herbal smoking) - to clear residual Kapha from respiratory passages
• Rest, warmth, avoidance of suppression of natural urges

Summary

• Vaman Karmukatva = the mechanism by which Vamana exerts its therapeutic effect
• The five drug properties - Ushna, Tikshna, Sukshma, Vyavayi, Vikasi - are the pharmacological basis
• The process works through: Mobilization → Expulsion → Purification → Restoration
• It cleanses Pranavaha Srotas, making it the single most important treatment for Tamak Shwas (Bronchial Asthma)
• Modern science correlates it with the medullary vomiting reflex, antiperistalsis, mucosal clearance, and airway detoxification
• Outcome: elimination of root-cause doshas, restoration of Agni, and long-term disease alleviation